Dr. Moyad on the history of vitamin D trials in urology
“It was vitamin E and selenium in 2011-2012. There was a lot of hype about it. People were very excited. They lost their excitement in urology about it, but then along came vitamin D,” says Mark A. Moyad, MD, MPH.
In this interview, Mark A. Moyad, MD, MPH discusses the 2011 Selenium and Vitamin E Cancer Prevention Trial (SELECT) and the recently completed VITamin D and OmegA-3 TriaL (VITAL), both of which explored the impact of vitamin D on urologic endpoints. Moyad is the Jenkins/Pomkempner Director of Complementary Alternative Medicine in the Department of Urology at the University of Michigan Medical Center.
Black men have higher risk of prostate cancer at any PSA level
November 14th 2023“These findings suggest that to reduce health disparities for Veterans in the prevention of prostate cancer, clinicians should consider an individual Veteran’s risk for prostate cancer including factors such as race and age," says Kyung Min Lee, PhD.
